Common Contracts
4 similar Separation Agreement contracts by Mirna Therapeutics, Inc., Synlogic, Inc.
SEPARATION AGREEMENTSeparation Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Texas
This Separation Agreement (the “Agreement”) by and between Paul Lammers (“Executive”) and Mirna Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective eight (8) days after Executive’s signature hereto (the “Effective Date”), unless Executive revokes his acceptance of this Agreement as provided in Section 5(c) below, with reference to the following facts:
SEPARATION AGREEMENTSeparation Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Texas
This Separation Agreement (the “Agreement”) by and between Alan Fuhrman (“Executive”) and Mirna Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective eight (8) days after Executive’s signature hereto (the “Effective Date”), unless Executive revokes his acceptance of this Agreement as provided in Section 5(c) below, with reference to the following facts:
SEPARATION AGREEMENTSeparation Agreement • July 11th, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Separation Agreement (the “Agreement”) by and between Casi DeYoung (“Executive”) and Mirna Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective eight (8) days after Executive’s signature hereto (the “Effective Date”), unless Executive revokes her acceptance of this Agreement as provided in Section 5(c) below, with reference to the following facts:
SEPARATION AGREEMENTSeparation Agreement • May 25th, 2017 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Separation Agreement (the “Agreement”) by and between Vincent O’Neill (“Executive”) and Mirna Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective eight (8) days after Executive’s signature hereto (the “Effective Date”), unless Executive revokes his acceptance of this Agreement as provided in Section 5(c) below, with reference to the following facts:
